Compounds > abaloparatide
Page last updated: 2024-11-13

abaloparatide

Description

abaloparatide: synthetic analog of human PTHrP (Parathyroid Hormone-Related Protein) [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID145705876
MeSH IDM000604476

Synonyms (3)

Synonym
abaloparatide
247062-33-5
abaloparatide acetate

Research Excerpts

Toxicity

abaloparatide-sMTS, 94. Administration site reactions were the most frequently reported adverse events.

ExcerptReferenceRelevance
" However, some concerns have been raised due to a somewhat higher occurrence of adverse effects (particularly with palpitations and increased heart rate) or the resultant discontinuation due to these adverse effects when compared to teriparatide."( Efficacy and safety of abaloparatide for the treatment of post-menopausal osteoporosis.
Chiodini, I; Falchetti, A; Gennari, L; Merlotti, D, 2019)		0.51
"Review of heart rate (HR), blood pressure (BP), and cardiovascular-related adverse events (AEs), including major adverse cardiovascular events (MACEs) and heart failure (HF) from: (a) ACTIVE (NCT01343004), a phase 3 trial that randomized 2463 postmenopausal women with osteoporosis to abaloparatide, teriparatide, or placebo for 18 months; (b) ACTIVExtend (NCT01657162), where participants from the abaloparatide and placebo arms received alendronate for 2 years; and (c) a pharmacology study in 55 healthy adults."( Cardiovascular Safety of Abaloparatide in Postmenopausal Women With Osteoporosis: Analysis From the ACTIVE Phase 3 Trial.
Cosman, F; Cummings, SR; Mitlak, B; Peterson, LR; Towler, DA; Wang, Y, 2020)		0.56
" In 1:1 propensity score matched cohorts, time to first NVF following index date, major adverse cardiovascular events (MACE), and MACE + heart failure (HF) were compared between cohorts using a Cox proportional hazards model."( Comparative effectiveness and cardiovascular safety of abaloparatide and teriparatide in postmenopausal women new to anabolic therapy: A US administrative claims database study.
Cooper, C; Cosman, F; Mitlak, B; Varughese, S; Wang, Y; Williams, SA, 2022)		0.72
" The most common (≥5%) treatment-emergent adverse events were injection site reaction, dizziness, nasopharyngitis, arthralgia, bronchitis, hypertension, and headache."( The Efficacy and Safety of Abaloparatide-SC in Men With Osteoporosis: A Randomized Clinical Trial.
Adachi, J; Binkley, N; Cardona, J; Chen, Y; Czerwinski, E; Kendler, D; Knychas, D; Lewiecki, EM; Li, YH; Mitlak, B; Orwoll, E; Pearman, L; Plebanski, R; Recknor, C; Saag, KG; Vokes, T, 2022)		0.72
" Administration site reactions were the most frequently reported adverse events (abaloparatide-sMTS, 94."( Efficacy and Safety of Transdermal Abaloparatide in Postmenopausal Women with Osteoporosis: A Randomized Study.
Annett, M; Binkley, N; Cardona, J; Czerwinski, E; Lawrence, M; Lewiecki, EM; Mitlak, B; Nattrass, SM; Pearman, L; Recknor, C; Silverman, S; Strzelecka, A; Valenzuela, G, 2023)		0.91
"14%) ABL-related adverse events (AEs) through data mining of Food and Drug Administration Adverse Event Reporting System (FAERS) retrospectively."( A real-world pharmacovigilance study of abaloparatide based on the FDA Adverse Event Reporting System (FAERS).
Cheng, Q; Shi, X; Sun, MH; Zhao, YZ; Zou, SP, 2023)		0.91

Dosage Studied

ExcerptRelevanceReference
" A dose-response was observed at 24 weeks across the three doses of abaloparatide-SC and placebo (p = 0."( Abaloparatide-SC improves trabecular microarchitecture as assessed by trabecular bone score (TBS): a 24-week randomized clinical trial.
Banks, K; Bilezikian, JP; Fitzpatrick, LA; Hans, D; Harris, AG; Hattersley, G; Leder, BZ; Shevroja, E; Zanchetta, JR, 2018)		0.48
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (111)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's67 (60.36)24.3611
2020's44 (39.64)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials27 (23.28%)5.53%
Reviews30 (25.86%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other59 (50.86%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (18)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
An Open-Label, Randomized, 4-Period Crossover Study Evaluating the Bioequivalence of Two Abaloparatide-sMTS Treatments and the Effect of Small Variations in Wear-Time in Healthy Women. [NCT04936984]Phase 136 participants (Actual)Interventional2020-11-16Completed
Effect of Abaloparatide on Lumbar Disc Degeneration [NCT03708926]Phase 20 participants (Actual)Interventional2021-03-31Withdrawn(stopped due to Inability to obtain drugs from supplier.)
An Open-Label, Single-Arm, Multicenter Study to Evaluate the Early Effects of Abaloparatide on Tissue-Based Indices of Bone Formation and Resorption [NCT03710889]Phase 323 participants (Actual)Interventional2018-09-20Completed
A Prospective, Single Arm Study to Evaluate the Pharmacokinetics, Pharmacodynamics, and Usability of Abaloparatide-sMTS in Postmenopausal Women With Low Bone Mineral Density [NCT04366726]Phase 122 participants (Actual)Interventional2019-04-09Completed
An Open-Label Phase 2 Study of Abaloparatide to Mitigate Distal Femoral Bone Loss Following Total Knee Arthroplasty [NCT04167163]Phase 458 participants (Actual)Interventional2020-01-10Active, not recruiting
Effect of PTH Analog on Union Rates of Type II Odontoid Fractures in Older Adults [NCT04760782]Phase 220 participants (Anticipated)Interventional2022-05-18Recruiting
A Phase I Pilot Study of Abaloparatide + Bevacizumab in Myelodysplastic Syndromes [NCT03746041]Phase 120 participants (Actual)Interventional2019-02-14Completed
An Open-Label, Randomized, 2-Cohort, 2-Period Crossover Pharmacokinetic Study of Abaloparatide-SC and Abaloparatide-sMTS in Healthy Men and Women [NCT04663464]Phase 152 participants (Actual)Interventional2020-11-16Completed
A Randomized, Parallel-Group, Phase 2 Dose-finding Study to Evaluate the Effects of BA058 in the Treatment of Postmenopausal Women With Osteoporosis [NCT00542425]Phase 2222 participants (Actual)Interventional2007-04-30Completed
A Randomized, Double-blind, Placebo-controlled, Phase 3 Multicenter Study to Evaluate the Safety and Efficacy of Abaloparatide-SC for the Treatment of Men With Osteoporosis [NCT03512262]Phase 3228 participants (Actual)Interventional2018-05-03Completed
Phase II Trial of Abaloparatide vs. Placebo in Post-Menopausal Women Receiving Initial Spinal Fusion Surgery [NCT03841058]Phase 272 participants (Anticipated)Interventional2019-08-14Recruiting
A Randomized, Double-blind, Placebo-Controlled, Comparative Multicenter Phase 3 Study to Evaluate the Safety and Efficacy of BA058 (Abaloparatide) for Injection for Prevention of Fracture in Ambulatory Postmenopausal Women With Severe Osteoporosis and at [NCT01343004]Phase 32,463 participants (Actual)Interventional2011-04-30Completed
Time to Healing, Loss of Fixation, and Loss of Alignment in Supracondylar Distal Femur Fractures Among a Geriatric Population Treated With Abaloparatide: A Double-Blind Placebo Controlled Study [NCT04626141]Phase 476 participants (Anticipated)Interventional2023-09-30Not yet recruiting
Abaloparatide Versus Placebo for Pelvic Fracture Healing - A Phase 2 Randomized Controlled Trial [NCT04249232]Phase 278 participants (Anticipated)Interventional2020-09-17Recruiting
A Retrospective, Observational Cohort Study Evaluating the Effectiveness and Cardiovascular Safety of Abaloparatide in Postmenopausal Women New to Anabolic Therapies [NCT04974723]16,000 participants (Anticipated)Observational2021-07-01Active, not recruiting
A Randomized, Non-inferiority, Phase 3, Open-label, Multicenter Study to Evaluate the Efficacy and Safety of Abaloparatide-sMTS for the Treatment of Postmenopausal Women With Osteoporosis (the wearABLe Study) [NCT04064411]Phase 3511 participants (Actual)Interventional2019-08-05Completed
Abaloparatide Added to Ongoing Denosumab vs Continued Denosumab Alone [NCT04467983]Phase 470 participants (Anticipated)Interventional2021-02-01Recruiting
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of BA058 Administered Via a Coated Transdermal Microarray Delivery System (BA058 Transdermal) in Healthy Postmenopausal Women With Osteoporosis [NCT01674621]Phase 2250 participants (Actual)Interventional2012-09-25Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

TrialOutcome
NCT00542425 (5) [back to overview]Change in Bone Mineral Density, Total Spine.
NCT00542425 (5) [back to overview]Change in Bone Mineral Density, Femoral Neck.
NCT00542425 (5) [back to overview]Change in Bone Mineral Density, Total Hip.
NCT00542425 (5) [back to overview]Change in Bone Mineral Density, Total Spine.
NCT00542425 (5) [back to overview]Change in Marker of Bone Metabolism, PINP
NCT01343004 (6) [back to overview]Percent Change in Bone Mineral Density (BMD) of Total Hip From Baseline to Month 18
NCT01343004 (6) [back to overview]Percent Change in Bone Mineral Density (BMD) of Lumbar Spine From Baseline to 18 Months
NCT01343004 (6) [back to overview]Number of Treatment-Emergent Adverse Events Associated With Hypercalcemia at 18 Months
NCT01343004 (6) [back to overview]Number of Participants With Non-vertebral Fractures at 18 Months
NCT01343004 (6) [back to overview]Number of Participants With New Vertebral Fractures at 18 Months
NCT01343004 (6) [back to overview]Percent Change in Bone Mineral Density (BMD) of Femoral Neck From Baseline to Month 18
NCT01674621 (14) [back to overview]Number of Participants With an Abnormal Clinical Hematology Laboratory Parameter With an Eastern Cooperative Oncology Group (ECOG) Score of Grade 3 or Grade 4
NCT01674621 (14) [back to overview]Number of Participants With an Abnormal Clinical Coagulation Laboratory Parameter With an ECOG Score of Grade 3 or Grade 4
NCT01674621 (14) [back to overview]Number of Participants With an Abnormal Clinical Chemistry Laboratory Parameter With an ECOG Score of Grade 3 or Grade 4
NCT01674621 (14) [back to overview]Number of Participants With a Clinically Meaningful Abnormal Electrocardiogram (ECG) Test Result
NCT01674621 (14) [back to overview]Percent Change From Baseline in Serum Bone-Specific Alkaline Phosphatase (BSAP) at 6 Months
NCT01674621 (14) [back to overview]Percent Change From Baseline in BMD of Forearm at 6 Months
NCT01674621 (14) [back to overview]Percent Change From Baseline in BMD of Total Hip at 6 Months
NCT01674621 (14) [back to overview]Percent Change From Baseline in Bone Mineral Density (BMD) of Lumbar Spine at 6 Months
NCT01674621 (14) [back to overview]Percent Change From Baseline in Serum Carboxy-terminal Cross-linking Telopeptide of Type I Collagen (CTXI) at 6 Months
NCT01674621 (14) [back to overview]Percent Change From Baseline in Serum Osteocalcin at 6 Months
NCT01674621 (14) [back to overview]Percent Change From Baseline in Serum Procollagen Type I C Propeptide (PICP) at 6 Months
NCT01674621 (14) [back to overview]Percent Change From Baseline in Serum Procollagen Type I N Propeptide (PINP) at 6 Months
NCT01674621 (14) [back to overview]Number of Participants With Abnormal Physical Examinations at Screening and End of Treatment (6 Months)
NCT01674621 (14) [back to overview]Number of Participants With Treatment Emergent Adverse Events (TEAEs) That Occurred During the Study That Were Associated With Vital Sign Changes
NCT03512262 (13) [back to overview]Percent Change From Baseline in Lumbar Spine BMD at Month 12
NCT03512262 (13) [back to overview]Percent of Participants Experiencing BMD Gains From Baseline of > 0%, > 3%, and > 6% at the Lumbar Spine, Femoral Neck, and Total Hip
NCT03512262 (13) [back to overview]Percent of Participants With Change in Disease Status
NCT03512262 (13) [back to overview]Percent Change in Total Hip BMD From Baseline at Month 6
NCT03512262 (13) [back to overview]Number of Participants With New Clinical Fractures
NCT03512262 (13) [back to overview]Percent Change From Baseline in Distal One-third Radius BMD at Month 12
NCT03512262 (13) [back to overview]Percent Change From Baseline in Femoral Neck BMD at Month 12
NCT03512262 (13) [back to overview]Percent Change From Baseline in Femoral Neck BMD at Month 6
NCT03512262 (13) [back to overview]Percent Change From Baseline in Lumbar Spine BMD at Month 6
NCT03512262 (13) [back to overview]Percent Change From Baseline in Serum Carboxy-terminal Cross-linking Telopeptide of Type I Collagen (s-CTX) at Month 12
NCT03512262 (13) [back to overview]Percent Change From Baseline in Serum Procollagen Type I N-terminal Propeptide (s-PINP) at Month 12
NCT03512262 (13) [back to overview]Percent Change From Baseline in Total Hip BMD at Month 12
NCT03512262 (13) [back to overview]Percent Change From Baseline in Ultra-Distal Radius BMD at Month 12
NCT03710889 (4) [back to overview]Change in Serum Procollagen Type I N-terminal Propeptide (s-P1NP) From Baseline at Month 1 and Month 3
NCT03710889 (4) [back to overview]Change in Serum Carboxy-Terminal Cross-Linking Telopeptide of Type I Collagen (s-CTX) From Baseline at Month 1 and Month 3
NCT03710889 (4) [back to overview]Change From Baseline in Mineralizing Surface/Bone Surface (MS/BS) in the Cancellous Envelope at Month 3
NCT03710889 (4) [back to overview]Change From Baseline in Bone Formation Rate/Bone Surface (BFR/BS) in the Cancellous Envelope at Month 3
NCT04064411 (3) [back to overview]Percent Change From Baseline in Femoral Neck BMD at Month 12
NCT04064411 (3) [back to overview]Percent Change From Baseline in Lumbar Spine BMD at Month 12
NCT04064411 (3) [back to overview]Percent Change From Baseline in Total Hip BMD at Month 12
NCT04366726 (6) [back to overview]Change From Baseline of Serum Phosphorus to Predose and Postdose on Day 29
NCT04366726 (6) [back to overview]Change From Baseline of Serum Calcium (Albumin-Corrected) to Predose and Postdose on Day 29
NCT04366726 (6) [back to overview]Percent Change From Baseline of Serum Procollagen Type I N-Terminal Propeptides (s-PINP) at Day 29
NCT04366726 (6) [back to overview]Change From Baseline of Cyclic Adenosine Monophosphate (cAMP) to Day 29
NCT04366726 (6) [back to overview]Abaloparatide Maximum Plasma Concentration (Cmax) on Day 29
NCT04366726 (6) [back to overview]Abaloparatide Area Under the Plasma Concentration-Time Curve From Time 0 to the Time of the Last Quantifiable Concentration (AUC0-t) on Day 29

Change in Bone Mineral Density, Total Spine.

Total analyzable spine bone mineral density (BMD) was analyzed by DXA at Week 24. (NCT00542425)
Timeframe: 6 months

InterventionPercent change from baseline (Mean)
Placebo1.22
BA058 20 µg3.30
BA058 40 µg5.21
BA058 80 µg6.11
Teriparatide5.47

[back to top]

Change in Bone Mineral Density, Femoral Neck.

Femoral neck bone mineral density (BMD) was analyzed by DXA at Week 24. (NCT00542425)
Timeframe: 6 months

InterventionPercent change from baseline (Mean)
Placebo0.79
BA058 20 µg2.69
BA058 40 µg2.20
BA058 80 µg3.07
Teriparatide1.07

[back to top]

Change in Bone Mineral Density, Total Hip.

Total analyzable hip bone mineral density (BMD) was analyzed by DXA at Week 24. (NCT00542425)
Timeframe: 6 months

InterventionPercent change from baseline (Mean)
Placebo0.39
BA058 20 µg1.43
BA058 40 µg1.97
BA058 80 µg2.60
Teriparatide0.45

[back to top]

Change in Bone Mineral Density, Total Spine.

Total analyzable spine bone mineral density (BMD) was analyzed by DXA at Week 48. (NCT00542425)
Timeframe: 12 months

InterventionPercent change from baseline (Mean)
Placebo0.74
BA058 20 µg5.14
BA058 40 µg9.84
BA058 80 µg12.94
Teriparatide8.63

[back to top]

Change in Marker of Bone Metabolism, PINP

PINP, N-terminal propeptide of type I procollagen, is a marker of anabolic bone growth. (NCT00542425)
Timeframe: 6 months

InterventionPercent change from baseline (Mean)
Placebo-13.1
BA058 20 µg20.0
BA058 40 µg90.8
BA058 80 µg97.2
Teriparatide154.3

[back to top]

Percent Change in Bone Mineral Density (BMD) of Total Hip From Baseline to Month 18

(NCT01343004)
Timeframe: Baseline and 18 months

Interventionpercent change (Mean)
Placebo-0.08
BA058 80 mcg (Abaloparatide)3.44
Teriparatide2.81

[back to top]

Percent Change in Bone Mineral Density (BMD) of Lumbar Spine From Baseline to 18 Months

(NCT01343004)
Timeframe: Basline and 18 months

Interventionpercent change from baseline (Mean)
Placebo0.48
BA058 80 mcg (Abaloparatide)9.20
Teriparatide9.12

[back to top]

Number of Treatment-Emergent Adverse Events Associated With Hypercalcemia at 18 Months

(NCT01343004)
Timeframe: 18 months

InterventionHypercalcemic events (Number)
Placebo5
BA058 80 mcg (Abaloparatide)15
Teriparatide34

[back to top]

Number of Participants With Non-vertebral Fractures at 18 Months

(NCT01343004)
Timeframe: 18 months

InterventionParticipants (Number)
Placebo33
BA058 80 mcg (Abaloparatide)18
Teriparatide24

[back to top]

Number of Participants With New Vertebral Fractures at 18 Months

(NCT01343004)
Timeframe: 18 months

Interventionparticipants (Number)
Placebo30
BA058 80 mcg (Abaloparatide)4
Teriparatide6

[back to top]

Percent Change in Bone Mineral Density (BMD) of Femoral Neck From Baseline to Month 18

(NCT01343004)
Timeframe: Baseline and 18 months

Interventionpercent change (Mean)
Placebo-0.44
BA058 80 mcg (Abaloparatide)2.90
Teriparatide2.26

[back to top]

Number of Participants With an Abnormal Clinical Hematology Laboratory Parameter With an Eastern Cooperative Oncology Group (ECOG) Score of Grade 3 or Grade 4

Hematology laboratory parameters that were evaluated via ECOG Grade 3 and Grade 4 criteria (presented in parentheses) included: white blood cell (Grade 3: 1.0-1.9*10^9/liter [L]; Grade 4 <1.0*10^9/L), platelets (Grade 3: 25.0-49.9*10^9/L; Grade 4: <25.0*10^9/L), haemoglobin (Grade 3: 65.0-79.0 grams [g]/L or 4.0-4.9 mmol/L; Grade 4: <65.0 g/L or <4.0 millimole [mmol]/L), granulocytes/bands (Grade 3: 0.5-0.9*10^9/L; Grade 4: <0.5*10^9/L), lymphocytes (Grade 3: 0.5-0.9*10^9/L; Grade 4: <0.5 *10^9/L), haemorrhage (Grade 3: gross, 3 - 4 units transfusion per episode; Grade 4: massive, > 4 units transfusion per episode). A summary of other non-serious AEs and all serious AEs, regardless of causality is located in Reported AE section. (NCT01674621)
Timeframe: Baseline up to 6 Months

InterventionParticipants (Count of Participants)
Abaloparatide Transdermal (50 mcg)6
Abaloparatide Transdermal (100 mcg)5
Abaloparatide Transdermal (150 mcg)4
Abaloparatide Injection (80 mcg)1
Abaloparatide Transdermal Placebo (0 mcg)5

[back to top]

Number of Participants With an Abnormal Clinical Coagulation Laboratory Parameter With an ECOG Score of Grade 3 or Grade 4

Coagulation laboratory parameters that were evaluated via ECOG Grade 3 and Grade 4 criteria (presented in parentheses) included: prothrombin time (quick) (Grade 3: 1.51%-2.00%*normal, Grade 4: >2.00%*normal), partial thromboplastin time (Grade 3: 2.34-3.00 seconds [sec], Grade 4: >3.00 secs*normal). A summary of other non-serious AEs and all serious AEs, regardless of causality is located in Reported AE section. (NCT01674621)
Timeframe: Baseline up to 6 Months

InterventionParticipants (Count of Participants)
Abaloparatide Transdermal (50 mcg)0
Abaloparatide Transdermal (100 mcg)0
Abaloparatide Transdermal (150 mcg)0
Abaloparatide Injection (80 mcg)0
Abaloparatide Transdermal Placebo (0 mcg)0

[back to top]

Number of Participants With an Abnormal Clinical Chemistry Laboratory Parameter With an ECOG Score of Grade 3 or Grade 4

Chemistry laboratory parameters that were evaluated via ECOG Grade 3 and Grade 4 criteria (presented in parentheses) included: sodium, potassium, chloride, inorganic phosphorus, albumin, total protein (Grade 3: 4 (+), >1.0 g%, or >10 g/L; Grade 4: nephrotic syndrome), glucose, blood urea nitrogen (BUN), creatinine (Grade 3: 3.1-6.0*normal; Grade 4: >6.0*normal), uric acid, aspartate aminotransferase (AST) (Grade 3: 5.1-20.0 units [U]/L*normal, Grade 4: >20.0 U/L*normal), alanine aminotransferase (ALT) (Grade 3: 5.1-20.0 U/L*normal; Grade 4: >20.0 U/L*normal), gamma-glutamyltranspeptidase (GGT), creatine phosphokinase (CPK), alkaline phosphatase (Grade 3: 5.1-20.0 U/L*normal; Grade 4: >20.0 U/L*normal), total bilirubin (Grade 3: 1.5-3.0*normal; Grade 4: >3.0*normal), lactate dehydrogenase (LDH), cholesterol, triglycerides, total calcium. A summary of other non-serious AEs and all serious AEs, regardless of causality is located in Reported AE section. (NCT01674621)
Timeframe: Baseline up to 6 Months

InterventionParticipants (Count of Participants)
Abaloparatide Transdermal (50 mcg)1
Abaloparatide Transdermal (100 mcg)0
Abaloparatide Transdermal (150 mcg)0
Abaloparatide Injection (80 mcg)0
Abaloparatide Transdermal Placebo (0 mcg)0

[back to top]

Number of Participants With a Clinically Meaningful Abnormal Electrocardiogram (ECG) Test Result

The following ECG parameters were recorded: rhythm, heart rate, PR interval, QRS duration and QT/QTc. ECG results that were considered clinically meaningful were to be determined by the Investigator. A summary of other non-serious AEs and all serious AEs, regardless of causality is located in Reported AE section. (NCT01674621)
Timeframe: Baseline up to 7 Months

InterventionParticipants (Count of Participants)
Abaloparatide Transdermal (50 mcg)0
Abaloparatide Transdermal (100 mcg)0
Abaloparatide Transdermal (150 mcg)1
Abaloparatide Injection (80 mcg)2
Abaloparatide Transdermal Placebo (0 mcg)0

[back to top]

Percent Change From Baseline in Serum Bone-Specific Alkaline Phosphatase (BSAP) at 6 Months

(NCT01674621)
Timeframe: Baseline, 6 Months

InterventionPercent change (Mean)
Abaloparatide Transdermal (50 mcg)-4.84
Abaloparatide Transdermal (100 mcg)5.22
Abaloparatide Transdermal (150 mcg)-5.52
Abaloparatide Injection (80 mcg)17.30
Abaloparatide Transdermal Placebo (0 mcg)10.23

[back to top]

Percent Change From Baseline in BMD of Forearm at 6 Months

Percent change in BMD as specified by DXA scans of the forearm. (NCT01674621)
Timeframe: Baseline, 6 Months

InterventionPercent change (Mean)
Abaloparatide Transdermal (50 mcg)-0.24
Abaloparatide Transdermal (100 mcg)-0.16
Abaloparatide Transdermal (150 mcg)0.84
Abaloparatide Injection (80 mcg)0.33
Abaloparatide Transdermal Placebo (0 mcg)0.05

[back to top]

Percent Change From Baseline in BMD of Total Hip at 6 Months

Percent change in BMD as specified by DXA scans of the total hip. (NCT01674621)
Timeframe: Baseline, 6 Months

InterventionPercent change (Mean)
Abaloparatide Transdermal (50 mcg)0.97
Abaloparatide Transdermal (100 mcg)1.32
Abaloparatide Transdermal (150 mcg)1.49
Abaloparatide Injection (80 mcg)2.74
Abaloparatide Transdermal Placebo (0 mcg)-0.02

[back to top]

Percent Change From Baseline in Bone Mineral Density (BMD) of Lumbar Spine at 6 Months

Percent change in BMD as specified by dual energy x-ray absorptiometry (DXA) scans of the lumbar spine. (NCT01674621)
Timeframe: Baseline, 6 Months

InterventionPercent change (Mean)
Abaloparatide Transdermal (50 mcg)1.87
Abaloparatide Transdermal (100 mcg)2.33
Abaloparatide Transdermal (150 mcg)2.95
Abaloparatide Injection (80 mcg)5.80
Abaloparatide Transdermal Placebo (0 mcg)0.04

[back to top]

Percent Change From Baseline in Serum Carboxy-terminal Cross-linking Telopeptide of Type I Collagen (CTXI) at 6 Months

(NCT01674621)
Timeframe: Baseline, 6 Months

InterventionPercent change (Mean)
Abaloparatide Transdermal (50 mcg)-2.61
Abaloparatide Transdermal (100 mcg)1.65
Abaloparatide Transdermal (150 mcg)-8.22
Abaloparatide Injection (80 mcg)41.11
Abaloparatide Transdermal Placebo (0 mcg)9.42

[back to top]

Percent Change From Baseline in Serum Osteocalcin at 6 Months

(NCT01674621)
Timeframe: Baseline, 6 Months

InterventionPercent change (Mean)
Abaloparatide Transdermal (50 mcg)-4.37
Abaloparatide Transdermal (100 mcg)6.67
Abaloparatide Transdermal (150 mcg)-3.83
Abaloparatide Injection (80 mcg)69.54
Abaloparatide Transdermal Placebo (0 mcg)-4.21

[back to top]

Percent Change From Baseline in Serum Procollagen Type I C Propeptide (PICP) at 6 Months

(NCT01674621)
Timeframe: Baseline, 6 Months

InterventionPercent change (Mean)
Abaloparatide Transdermal (50 mcg)-17.26
Abaloparatide Transdermal (100 mcg)-8.42
Abaloparatide Transdermal (150 mcg)-16.63
Abaloparatide Injection (80 mcg)10.28
Abaloparatide Transdermal Placebo (0 mcg)-6.76

[back to top]

Percent Change From Baseline in Serum Procollagen Type I N Propeptide (PINP) at 6 Months

(NCT01674621)
Timeframe: Baseline, 6 Months

InterventionPercent change (Mean)
Abaloparatide Transdermal (50 mcg)-12.76
Abaloparatide Transdermal (100 mcg)1.52
Abaloparatide Transdermal (150 mcg)-6.78
Abaloparatide Injection (80 mcg)97.64
Abaloparatide Transdermal Placebo (0 mcg)-7.26

[back to top]

Number of Participants With Abnormal Physical Examinations at Screening and End of Treatment (6 Months)

A full physical examination included, at a minimum: general appearance, skin, head/ears/eyes/nose/throat, lungs/chest, breasts, heart, abdomen, lymph nodes, musculoskeletal, extremities, and neurologic. Physical examination results that were considered abnormal were determined by the Investigator. A summary of other non-serious adverse events (AEs) and all serious AEs (SAEs), regardless of causality is located in Reported AE section. (NCT01674621)
Timeframe: Baseline up to 6 Months

,,,,
InterventionParticipants (Count of Participants)
General appearance at ScreeningGeneral appearance at 6 monthsSkin at ScreeningSkin at 6 monthsHead at ScreeningHead at 6 monthsLungs at ScreeningLungs at 6 monthsBreasts at ScreeningBreasts at 6 monthsAbdomen at ScreeningAbdomen at 6 monthsLymph nodes at ScreeningLymph nodes at 6 monthsColumna at ScreeningColumna at 6 monthsExtremities at ScreeningExtremities at 6 monthsNeurologic at ScreeningNeurologic at 6 months
Abaloparatide Injection (80 mcg)111414541134990043232523
Abaloparatide Transdermal (100 mcg)002426340077870032131000
Abaloparatide Transdermal (150 mcg)011716230033431077141400
Abaloparatide Transdermal (50 mcg)002829660044760011212300
Abaloparatide Transdermal Placebo (0 mcg)00211712101110430111212111

[back to top]

Number of Participants With Treatment Emergent Adverse Events (TEAEs) That Occurred During the Study That Were Associated With Vital Sign Changes

Vital sign parameters included respiration rate (breaths/minute), body temperature (°C), systolic blood pressure (SBP) and diastolic blood pressure (DBP) (mmHg), and heart rate (bpm). Number of participants for each TEAE is presented. The same participant may be included in more than one TEAE category. A summary of other non-serious AEs and all serious AEs, regardless of causality is located in Reported AE section. (NCT01674621)
Timeframe: Baseline up to 7 Months

,,,,
InterventionParticipants (Count of Participants)
HypertensionBlood Pressure IncreasedHeart Rate increasedDyspnoeaDizziness
Abaloparatide Injection (80 mcg)01011
Abaloparatide Transdermal (100 mcg)10000
Abaloparatide Transdermal (150 mcg)01100
Abaloparatide Transdermal (50 mcg)00000
Abaloparatide Transdermal Placebo (0 mcg)00000

[back to top]

Percent Change From Baseline in Lumbar Spine BMD at Month 12

Lumbar Spine BMD was assessed by DXA scans evaluated by a central imaging laboratory. Lumbar spine scans included L1 through L4. Positive changes from baseline indicate improvement in bone health. (NCT03512262)
Timeframe: Baseline, Month 12

Interventionpercent change (Least Squares Mean)
Abaloparatide8.4820
Placebo1.1654

[back to top]

Percent of Participants Experiencing BMD Gains From Baseline of > 0%, > 3%, and > 6% at the Lumbar Spine, Femoral Neck, and Total Hip

Lumbar spine, femoral neck, and total hip BMD were assessed by DXA scans evaluated by a central imaging laboratory. (NCT03512262)
Timeframe: Month 12

,
Interventionpercentage of participants (Number)
BMD Increase >0% at All Three SitesBMD Increase >3% at All Three SitesBMD Increase >6% at All Three Sites
Abaloparatide67.231.99.2
Placebo15.21.50.0

[back to top]

Percent of Participants With Change in Disease Status

"The percentage of participants converting from the categories of osteoporosis to osteopenia or from osteopenia to normal at End of Treatment (Month 12) was assessed. Osteoporosis was defined as lumbar spine or total hip BMD T-score ≤ -2.5. Osteopenia was defined as one of the following:~Lumbar spine > -2.5 and total hip BMD T-score > -2.5 and < -1.0~Lumbar spine > -2.5 and < -1.0 and total hip BMD T-score > -2.5~Normal was defined as lumbar spine and total hip BMD T-score ≥ -1.0." (NCT03512262)
Timeframe: Baseline through Month 12

,
Interventionpercentage of participants (Number)
Osteopenia to NormalOsteopenia to OsteoporosisOsteoporosis to NormalOsteoporosis to OsteopeniaNormal to Osteopenia or Osteoporosis
Abaloparatide8.802.957.10
Placebo8.012.0012.80

[back to top]

Percent Change in Total Hip BMD From Baseline at Month 6

Total hip BMD was assessed by DXA scans evaluated by a central imaging laboratory. Positive changes from baseline indicate improvement in bone health. (NCT03512262)
Timeframe: Baseline, Month 6

Interventionpercent change (Least Squares Mean)
Abaloparatide1.3888
Placebo0.0267

[back to top]

Number of Participants With New Clinical Fractures

Radiological evaluations were performed to identify any new clinical fractures (occurring after the screening visit). (NCT03512262)
Timeframe: Baseline through Month 12

InterventionParticipants (Count of Participants)
Abaloparatide1
Placebo3

[back to top] [back to top]

Percent Change From Baseline in Femoral Neck BMD at Month 12

Femoral neck BMD was assessed by DXA scans evaluated by a central imaging laboratory. Positive changes from baseline indicate improvement in bone health. (NCT03512262)
Timeframe: Baseline, Month 12

Interventionpercent change (Least Squares Mean)
Abaloparatide2.9766
Placebo0.1545

[back to top]

Percent Change From Baseline in Femoral Neck BMD at Month 6

Femoral neck BMD was assessed by DXA scans evaluated by a central imaging laboratory. Positive changes from baseline indicate improvement in bone health. (NCT03512262)
Timeframe: Baseline, Month 6

Interventionpercent change (Least Squares Mean)
Abaloparatide1.4790
Placebo-0.1884

[back to top]

Percent Change From Baseline in Lumbar Spine BMD at Month 6

Lumbar Spine BMD was assessed by DXA scans evaluated by a central imaging laboratory. Lumbar spine scans included L1 through L4. Positive changes from baseline indicate improvement in bone health. (NCT03512262)
Timeframe: Baseline, Month 6

Interventionpercent change (Least Squares Mean)
Abaloparatide5.5436
Placebo0.6418

[back to top]

Percent Change From Baseline in Serum Carboxy-terminal Cross-linking Telopeptide of Type I Collagen (s-CTX) at Month 12

Blood samples were taken to measure s-CTX. Elevated levels of s-CTX indicate increased bone resorption (bone loss). (NCT03512262)
Timeframe: Baseline, Month 12

Interventionpercent change (Mean)
Abaloparatide89.639
Placebo15.359

[back to top]

Percent Change From Baseline in Serum Procollagen Type I N-terminal Propeptide (s-PINP) at Month 12

Blood samples were taken to measure s-PINP, a bone formation marker. s-PINP concentrations reflect the rate of skeletal new bone formation. Increases in s-PINP indicate anabolic biologic response in the bone. (NCT03512262)
Timeframe: Baseline, Month 12

Interventionpercent change (Mean)
Abaloparatide225.919
Placebo0.291

[back to top]

Percent Change From Baseline in Total Hip BMD at Month 12

Total hip BMD was assessed by DXA scans evaluated by a central imaging laboratory. Positive changes from baseline indicate improvement in bone health. (NCT03512262)
Timeframe: Baseline, Month 12

Interventionpercent change (Least Squares Mean)
Abaloparatide2.1351
Placebo0.0143

[back to top]

Percent Change From Baseline in Ultra-Distal Radius BMD at Month 12

Ultra-distal radius BMD was assessed by DXA scans. Positive changes from baseline indicate improvement in bone health. (NCT03512262)
Timeframe: Baseline, Month 12

Interventionpercent change (Least Squares Mean)
Abaloparatide1.4358
Placebo-0.1915

[back to top]

Change in Serum Procollagen Type I N-terminal Propeptide (s-P1NP) From Baseline at Month 1 and Month 3

Blood samples were taken to measure efficacy related markers of bone metabolism at Day 1, Month 1, and Month 3. (NCT03710889)
Timeframe: Baseline (Day 1), Months 1 and 3

Interventionnanograms (ng)/milliliter (mL) (Median)
BaselineChange at Month 1Change at Month 3
Abaloparatide54.990119.155141.130

[back to top]

Change in Serum Carboxy-Terminal Cross-Linking Telopeptide of Type I Collagen (s-CTX) From Baseline at Month 1 and Month 3

Blood samples were taken to measure efficacy-related markers of bone metabolism at Day 1, Month 1, and Month 3. (NCT03710889)
Timeframe: Baseline (Day 1), Months 1 and 3

Interventionng/mL (Median)
BaselineChange at Month 1Change at Month 3
Abaloparatide0.4600.0520.311

[back to top]

Change From Baseline in Mineralizing Surface/Bone Surface (MS/BS) in the Cancellous Envelope at Month 3

Change in dynamic histomorphometry indices was assessed in the cancellous envelope. (NCT03710889)
Timeframe: Baseline (Day 1), Month 3

Interventionpercentage of MS/BS (Mean)
BaselineChange at Month 3
Abaloparatide5.7418.66

[back to top]

Change From Baseline in Bone Formation Rate/Bone Surface (BFR/BS) in the Cancellous Envelope at Month 3

Change in dynamic histomorphometry indices was assessed in the cancellous envelope. BFR/BS was reported as cubic millimeter/square millimeter/year (mm^3/mm^2/year). (NCT03710889)
Timeframe: Baseline (Day 1), Month 3

Interventionmm^3/mm^2/year (Mean)
BaselineChange at Month 3
Abaloparatide0.0110.034

[back to top]

Percent Change From Baseline in Femoral Neck BMD at Month 12

Femoral neck BMD was assessed by DXA scans evaluated by a central imaging laboratory. (NCT04064411)
Timeframe: Baseline, Month 12

Interventionpercent change (Least Squares Mean)
Abaloparatide-SC3.4159
Abaloparatide-sMTS1.9163

[back to top]

Percent Change From Baseline in Lumbar Spine BMD at Month 12

Lumbar Spine BMD was assessed by DXA scans evaluated by a central imaging laboratory. (NCT04064411)
Timeframe: Baseline, Month 12

Interventionpercent change (Least Squares Mean)
Abaloparatide-SC10.8571
Abaloparatide-sMTS7.1361

[back to top]

Percent Change From Baseline in Total Hip BMD at Month 12

Total hip BMD was assessed by DXA scans evaluated by a central imaging laboratory. (NCT04064411)
Timeframe: Baseline, Month 12

Interventionpercent change (Least Squares Mean)
Abaloparatide-SC3.6995
Abaloparatide-sMTS1.9688

[back to top]

Change From Baseline of Serum Phosphorus to Predose and Postdose on Day 29

(NCT04366726)
Timeframe: Baseline, 0 (predose) and 4 hours postdose on Day 29

Interventionmmol/L (Mean)
Day 29, predoseDay 29, postdose
Abaloparatide-sMTS0.0510.006

[back to top]

Change From Baseline of Serum Calcium (Albumin-Corrected) to Predose and Postdose on Day 29

(NCT04366726)
Timeframe: Baseline, 0 (predose) and 4 hours postdose on Day 29

Interventionmillimoles/liter (mmol/L) (Mean)
Day 29, predoseDay 29, postdose
Abaloparatide-sMTS-0.031-0.002

[back to top]

Percent Change From Baseline of Serum Procollagen Type I N-Terminal Propeptides (s-PINP) at Day 29

Blood samples were taken to measure s-PINP, a bone formation marker. s-PINP concentrations reflect the rate of skeletal new bone formation. Increases in s-PINP indicate anabolic biologic response in the bone. (NCT04366726)
Timeframe: Baseline, Day 29

Interventionpercent change (Mean)
Abaloparatide-sMTS103.16

[back to top]

Change From Baseline of Cyclic Adenosine Monophosphate (cAMP) to Day 29

(NCT04366726)
Timeframe: Baseline, 0 (predose) and 30-minutes postdose on Day 29

Interventionmicromoles/liter (μmol/L) (Mean)
Day 29, predoseDay 29, postdose
Abaloparatide-sMTS-0.0030-0.0006

[back to top]

Abaloparatide Maximum Plasma Concentration (Cmax) on Day 29

(NCT04366726)
Timeframe: 0 (predose), 10 minutes, 20 minutes, 30 minutes, 1 hour, 1.5 hours, 2 hours, 3 hours, and 4 hours postdose on Day 29

Interventionpicograms/milliliter (pg/mL) (Geometric Mean)
Abaloparatide-sMTS399.6

[back to top]

Abaloparatide Area Under the Plasma Concentration-Time Curve From Time 0 to the Time of the Last Quantifiable Concentration (AUC0-t) on Day 29

(NCT04366726)
Timeframe: 0 (predose) and 4 hours postdose on Day 29

Interventionhour*pg/mL (Geometric Mean)
Abaloparatide-sMTS604.7

[back to top]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
alendronate
alendronic acid : A 1,1-bis(phosphonic acid) that is methanebis(phosphonic acid) in which the two methylene hydrogens are replaced by hydroxy and 3-aminopropyl groups.		11.181581,1-bis(phosphonic acid);
primary amino compound		bone density conservation agent;
EC 2.5.1.1 (dimethylallyltranstransferase) inhibitor
metronidazole
Metronidazole: A nitroimidazole used to treat AMEBIASIS; VAGINITIS; TRICHOMONAS INFECTIONS; GIARDIASIS; ANAEROBIC BACTERIA; and TREPONEMAL INFECTIONS.. metronidazole : A member of the class of imidazoles substituted at C-1, -2 and -5 with 2-hydroxyethyl, nitro and methyl groups respectively. It has activity against anaerobic bacteria and protozoa, and has a radiosensitising effect on hypoxic tumour cells. It may be given by mouth in tablets, or as the benzoate in an oral suspension. The hydrochloride salt can be used in intravenous infusions. Metronidazole is a prodrug and is selective for anaerobic bacteria due to their ability to intracellularly reduce the nitro group of metronidazole to give nitroso-containing intermediates. These can covalently bind to DNA, disrupting its helical structure, inducing DNA strand breaks and inhibiting bacterial nucleic acid synthesis, ultimately resulting in bacterial cell death.		2.1710C-nitro compound;
imidazoles;
primary alcohol		antiamoebic agent;
antibacterial drug;
antimicrobial agent;
antiparasitic agent;
antitrichomonal drug;
environmental contaminant;
prodrug;
radiosensitizing agent;
xenobiotic
methylprednisolone
Methylprednisolone: A PREDNISOLONE derivative with similar anti-inflammatory action.. 6alpha-methylprednisolone : The 6alpha-stereoisomer of 6-methylprednisolone.		2.21106-methylprednisolone;
primary alpha-hydroxy ketone;
tertiary alpha-hydroxy ketone		adrenergic agent;
anti-inflammatory drug;
antiemetic;
environmental contaminant;
neuroprotective agent;
xenobiotic
thiophenes
Thiophenes: A monocyclic heteroarene furan in which the oxygen atom is replaced by a sulfur.. thiophenes : Compounds containing at least one thiophene ring.		9.2280mancude organic heteromonocyclic parent;
monocyclic heteroarene;
thiophenes;
volatile organic compound		non-polar solvent
quinazolines
Quinazolines: A group of aromatic heterocyclic compounds that contain a bicyclic structure with two fused six-membered aromatic rings, a benzene ring and a pyrimidine ring.. quinazoline : A mancude organic heterobicyclic parent that is naphthalene in which the carbon atoms at positions 1 and 3 have been replaced by nitrogen atoms.. quinazolines : Any organic heterobicyclic compound based on a quinazoline skeleton and its substituted derivatives.		2.1710azaarene;
mancude organic heterobicyclic parent;
ortho-fused heteroarene;
quinazolines
azomycin
azomycin: RN given refers to parent cpd with specified locant; structure		2.1710C-nitro compound;
imidazoles		antitubercular agent
phenyl acetate
phenyl acetate: The ester formed between phenol and acetic acid. Don't confuse with phenylacetic acid derivatives listed under PHENYLACETATES.. phenyl acetate : An acetate ester obtained by the formal condensation of phenol with acetic acid.		2.1710benzenes;
phenyl acetates
benzonidazole
benzonidazole: used in treatment of Chagas' disease. benznidazole : A monocarboxylic acid amide obtained by formal condensation of the carboxy group of (2-nitroimidazol-1-yl)acetic acid with the aromatic amino group of benzylamine. Used for treatment of Chagas disease.		2.1710C-nitro compound;
imidazoles;
monocarboxylic acid amide		antiprotozoal drug
raloxifene hydrochloride
Raloxifene Hydrochloride: A second generation selective estrogen receptor modulator (SERM) used to prevent osteoporosis in postmenopausal women. It has estrogen agonist effects on bone and cholesterol metabolism but behaves as a complete estrogen antagonist on mammary gland and uterine tissue.. raloxifene hydrochloride : A hydrochloride salt resulting from the reaction of equimolar amounts of raloxifene and hydrogen chloride.		9.4190hydrochloridebone density conservation agent;
estrogen antagonist;
estrogen receptor modulator
secnidazole
[no description available]		2.1710C-nitro compound;
imidazoles;
secondary alcohol		epitope
bazedoxifene
[no description available]		9.2280phenylindole
meropenem
Meropenem: A thienamycin derivative antibacterial agent that is more stable to renal dehydropeptidase I than IMIPENEM, but does not need to be given with an enzyme inhibitor such as CILASTATIN. It is used in the treatment of bacterial infections, including infections in immunocompromised patients.. meropenem : A carbapenemcarboxylic acid in which the azetidine and pyrroline rings carry 1-hydroxymethyl and in which the azetidine and pyrroline rings carry 1-hydroxymethyl and 5-(dimethylcarbamoyl)pyrrolidin-3-ylthio substituents respectively.		2.1710alpha,beta-unsaturated monocarboxylic acid;
carbapenemcarboxylic acid;
organic sulfide;
pyrrolidinecarboxamide		antibacterial agent;
antibacterial drug;
drug allergen
tibolone
tibolone: used in prevention of postmenopausal osteoporosis. tibolone : Estran-3-one with a double bond between positions 5 and 10, and bearing both an ethynyl group and a hydroxy group at position 17 (R-configuration). A synthetic steroid hormone drug which acts as an agonist at all five type I steroid hormone receptors, it is used in the prevention of postmenopausal osteoporosis and for treatment of endometriosis.		3.121017beta-hydroxy steroid;
terminal acetylenic compound		bone density conservation agent;
hormone agonist
abt 492
WQ 3034: structure in first source		2.1710
calcitriol
dihydroxy-vitamin D3: as a major in vitro metabolite of 1alpha,25-dihydroxyvitamin D3, produced in primary cultures of neonatal human keratinocytes		3.0120D3 vitamins;
hydroxycalciol;
triol		antineoplastic agent;
antipsoriatic;
bone density conservation agent;
calcium channel agonist;
calcium channel modulator;
hormone;
human metabolite;
immunomodulator;
metabolite;
mouse metabolite;
nutraceutical
odanacatib
odanacatib: a selective inhibitor of cathepsin K for the treatment of post-menopausal osteoporosis; structure in first source		3.1910
letermovir
letermovir: has antiviral activity; structure in first source		2.1710
rpx7009
RPX7009: a beta-lactamase inhibitor; structure in first source		2.1710
guanosine 5'-o-(3-thiotriphosphate)
Guanosine 5'-O-(3-Thiotriphosphate): Guanosine 5'-(trihydrogen diphosphate), monoanhydride with phosphorothioic acid. A stable GTP analog which enjoys a variety of physiological actions such as stimulation of guanine nucleotide-binding proteins, phosphoinositide hydrolysis, cyclic AMP accumulation, and activation of specific proto-oncogenes.		3.0410nucleoside triphosphate analogue
ConditionIndicatedRelationship StrengthStudiesTrials
Low Bone Density
[description not available]		03.6270
Bone Diseases, Metabolic
Diseases that affect the METABOLIC PROCESSES of BONE TISSUE.		03.6270
Intertrochanteric Fractures
[description not available]		07.3151
Bone Loss, Perimenopausal
[description not available]		021.0313043
Hip Fractures
Fractures of the FEMUR HEAD; the FEMUR NECK; (FEMORAL NECK FRACTURES); the trochanters; or the inter- or subtrochanteric region. Excludes fractures of the acetabulum and fractures of the femoral shaft below the subtrochanteric region (FEMORAL FRACTURES).		07.3151
Osteoporosis, Postmenopausal
Metabolic disorder associated with fractures of the femoral neck, vertebrae, and distal forearm. It occurs commonly in women within 15-20 years after menopause, and is caused by factors associated with menopause including estrogen deficiency.		021.0313043
Osteoporotic Fractures
Breaks in bones resulting from low bone mass and microarchitectural deterioration characteristic of OSTEOPOROSIS.		017.576238
Pericementitis
[description not available]		03.5210
Alveolar Bone Atrophy
[description not available]		03.5210
Periodontitis
Inflammation and loss of connective tissues supporting or surrounding the teeth. This may involve any part of the PERIODONTIUM. Periodontitis is currently classified by disease progression (CHRONIC PERIODONTITIS; AGGRESSIVE PERIODONTITIS) instead of age of onset. (From 1999 International Workshop for a Classification of Periodontal Diseases and Conditions, American Academy of Periodontology)		08.5210
Age-Related Osteoporosis
[description not available]		014.975010
Osteoporosis
Reduction of bone mass without alteration in the composition of bone, leading to fractures. Primary osteoporosis can be of two major types: postmenopausal osteoporosis (OSTEOPOROSIS, POSTMENOPAUSAL) and age-related or senile osteoporosis.		014.975010
Glenoid Labral Tears
[description not available]		03.750
Rotator Cuff Injuries
Injuries to the ROTATOR CUFF of the shoulder joint.		03.750
Bone Fractures
[description not available]		08.272
Fractures, Bone
Breaks in bones.		08.272
Benign Neoplasms
[description not available]		02.610
Neoplasms
New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.		02.610
Injuries, Spinal Cord
[description not available]		02.610
Spinal Cord Injuries
Penetrating and non-penetrating injuries to the spinal cord resulting from traumatic external forces (e.g., WOUNDS, GUNSHOT; WHIPLASH INJURIES; etc.).		02.610
Hangman Fracture
[description not available]		020.129728
Spinal Fractures
Broken bones in the vertebral column.		020.129728
Anorexia Nervosa
An eating disorder that is characterized by the lack or loss of APPETITE, known as ANOREXIA. Other features include excess fear of becoming OVERWEIGHT; BODY IMAGE disturbance; significant WEIGHT LOSS; refusal to maintain minimal normal weight; and AMENORRHEA. This disorder occurs most frequently in adolescent females. (APA, Thesaurus of Psychological Index Terms, 1994)		02.2510
Cardiac Failure
[description not available]		07.6844
Heart Failure
A heterogeneous condition in which the heart is unable to pump out sufficient blood to meet the metabolic need of the body. Heart failure can be caused by structural defects, functional abnormalities (VENTRICULAR DYSFUNCTION), or a sudden overload beyond its capacity. Chronic heart failure is more common than acute heart failure which results from sudden insult to cardiac function, such as MYOCARDIAL INFARCTION.		07.6844
Diabetes Mellitus, Adult-Onset
[description not available]		03.1710
Diabetes Mellitus, Type 2
A subclass of DIABETES MELLITUS that is not INSULIN-responsive or dependent (NIDDM). It is characterized initially by INSULIN RESISTANCE and HYPERINSULINEMIA; and eventually by GLUCOSE INTOLERANCE; HYPERGLYCEMIA; and overt diabetes. Type II diabetes mellitus is no longer considered a disease exclusively found in adults. Patients seldom develop KETOSIS but often exhibit OBESITY.		03.1710
Bone Loss, Osteoclastic
[description not available]		05.2970
Chronic Kidney Diseases
[description not available]		014.97650
Fracture, Pathologic
[description not available]		014.97650
Renal Insufficiency, Chronic
Conditions in which the KIDNEYS perform below the normal level for more than three months. Chronic kidney insufficiency is classified by five stages according to the decline in GLOMERULAR FILTRATION RATE and the degree of kidney damage (as measured by the level of PROTEINURIA). The most severe form is the end-stage renal disease (CHRONIC KIDNEY FAILURE). (Kidney Foundation: Kidney Disease Outcome Quality Initiative, 2002)		014.97650
Bone Cancer
[description not available]		02.1510
Osteogenic Sarcoma
[description not available]		02.1510
Bone Neoplasms
Tumors or cancer located in bone tissue or specific BONES.		02.1510
Osteosarcoma
A sarcoma originating in bone-forming cells, affecting the ends of long bones. It is the most common and most malignant of sarcomas of the bones, and occurs chiefly among 10- to 25-year-old youths. (From Stedman, 25th ed)		02.1510
Femur Neck Fractures
[description not available]		03.5311
Femoral Neck Fractures
Fractures of the short, constricted portion of the thigh bone between the femur head and the trochanters. It excludes intertrochanteric fractures which are HIP FRACTURES.		03.5311
Recrudescence
[description not available]		03.0910
Hypertrophy
General increase in bulk of a part or organ due to CELL ENLARGEMENT and accumulation of FLUIDS AND SECRETIONS, not due to tumor formation, nor to an increase in the number of cells (HYPERPLASIA).		02.2110
Femoral Fractures
Fractures of the femur.		03.1210
Milk-Alkali Syndrome
[description not available]		012.361716
Hypercalcemia
Abnormally high level of calcium in the blood.		012.361716
Injuries, Wrist
[description not available]		04.9221
Radius Fractures
Fractures of the RADIUS.		03.5911
Disease Models, Animal
Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.		02.2110
Bone Diseases
Diseases of BONES.		02.2110
CKD-MBD
[description not available]		03.1210
Chronic Kidney Disease-Mineral and Bone Disorder
Decalcification of bone or abnormal bone development due to chronic KIDNEY DISEASES, in which 1,25-DIHYDROXYVITAMIN D3 synthesis by the kidneys is impaired, leading to reduced negative feedback on PARATHYROID HORMONE. The resulting SECONDARY HYPERPARATHYROIDISM eventually leads to bone disorders.		03.1210
chemdatabank.com